Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma

Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma

Bibliographic Details
Main Author:	Won Sohn
Format:	Article
Language:	English
Published:	The Korean Association of Internal Medicine 2021-03-01
Series:	The Korean Journal of Internal Medicine
Online Access:	http://www.kjim.org/upload/pdf/kjim-2021-078.pdf

Similar Items

Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan
by: Chen-Ta Chi, et al.
Published: (2021-06-01)

Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
by: Seong Kyun Na, et al.
Published: (2019-09-01)

The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma
by: Paulina Chinchilla-López, et al.
Published: (2017-05-01)

Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C
by: Jason J. Pan, et al.
Published: (2018-11-01)

The impact of achieving a sustained virological response with direct-acting antivirals on serum autotaxin levels in chronic hepatitis C patients
by: Shereen Abou Bakr Saleh, et al.
Published: (2020-11-01)

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence
by: Nevine Ibrahim Musa, et al.
Published: (2020-07-01)

Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.
by: Wei-Chen Lin, et al.
Published: (2020-01-01)

Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals
by: Kazunori Yoh, et al.
Published: (2017-10-01)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017-10-01)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
by: Chung Sang Tse, et al.
Published: (2021-01-01)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
by: Byung Soo Kwan, et al.
Published: (2021-03-01)

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
by: Chung-Feng Huang, et al.
Published: (2019-03-01)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
by: Hye Won Lee, et al.
Published: (2020-11-01)

The role of shear wave elastography in the dynamic monitoring of fibrosis in patients with chronic hepatitis C with sustained virological response after direct acting antiviral therapy
by: Mihaela C. OLARIU, et al.
Published: (2019-12-01)

Research advances in risk factors for hepatocellular carcinoma in chronic hepatitis C patients with sustained virologic response
by: YANG Luxuan, et al.
Published: (2017-03-01)

Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
by: Dash S, et al.
Published: (2020-04-01)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
by: Peter Karayiannis
Published: (2012-01-01)

Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct‐acting antivirals—A prospective study
by: Haley Pritchard, et al.
Published: (2020-06-01)

INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES
by: Vanessa Gutierrez de ANDRADE, et al.

Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes
by: Juliana Piedade, et al.
Published: (2021-06-01)

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed
by: Hassany SM, et al.
Published: (2020-06-01)

Antiviral therapy and risk for hepatocellular carcinoma in chronic viral hepatitis
by: D T Abdurakhmanov
Published: (2013-10-01)

Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs
by: Martynas Ridziauskas, et al.
Published: (2021-02-01)

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review
by: Mohamed El Kassas, et al.
Published: (2019-05-01)

Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
by: Cátia Dias, et al.
Published: (2018-01-01)

Hepatocellular carcinoma after direct-acting antiviral therapy in kidney transplant recipients infected with hepatitis C virus
by: Rita Calça, et al.
Published: (2020-11-01)

Hepatocellular carcinoma after direct-acting antiviral therapy in kidney transplant recipients infected with hepatitis C virus
by: Rita Calça, et al.
Published: (2020-11-01)

Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
by: Pil Soo Sung, et al.
Published: (2021-01-01)

Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?
by: Shih-Jer Hsu, et al.
Published: (2020-01-01)

Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases
by: R. Tapia-Sosa, et al.
Published: (2021-04-01)

Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response
by: Vabhave Pal, et al.
Published: (2020-01-01)

Refractory Hepatic Hydrothorax in Chronic Hepatitis C Controlled by Direct-acting Antivirals
by: Myung Hee Kim, et al.
Published: (2020-02-01)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
by: Sara Kishta, et al.
Published: (2020-06-01)

IL-28B single nucleotide polymorphism as a predictor of hepatocellular carcinoma after treatment of chronic hepatitis C patients with direct acting antivirals
by: Nancy Abdel Fattah Ahmed, et al.
Published: (2021-05-01)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
by: Eric R. Yoo, et al.
Published: (2016-01-01)

Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals
by: Alexandre Pariente, et al.
Published: (2019-01-01)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
by: Irina RUSU, et al.
Published: (2020-03-01)

Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
by: Minosse C, et al.
Published: (2018-11-01)

HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT
by: Angelo Alves de MATTOS, et al.
Published: (2015-12-01)

Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
by: Kazuaki Tabu, et al.
Published: (2020-01-01)

Cannot write session to /tmp/vufind_sessions/sess_bh6e8kia1qk7b065os1mkntsoc